Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
IPO Year:
Exchange: NASDAQ
Website: edesabiotech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2021 | $16.00 | Buy | HC Wainwright & Co. |
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario. Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the conference's online portal or contact the company directly at [email protected]. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company develop
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2024 and provided an update on its business. During the quarter, the company advanced its main asset, EB06, an anti-CXCL10 monoclonal antibody candidate being developed for the effective and durable treatment of vitiligo. Preparation for the manufacturing campaign is underway, with data anticipated to be submitted to regulators at the U.S. Food and Drug Administration (FDA) during the middle of 2025. The company in
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa's CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has sold, in a private placement, an aggregate of 834 newly designated Series B-1 convertible preferred shares ("Series B-1 Preferred Shares") and 3,468,746 common shares in a private placement priced at-the-market under the rules
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project f
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa's Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an immediate investment of approximately $1.5 million. The entity will purchase shares of the company's Series A-1 Convertible Preferred Shares, as amended (the "Series A-1 Preferred Shares"), having a stated value of $10,000 per share, and warrants (the "Warrants") to pur
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Stockholm, Sweden, November 4-6, 2024Dermatology Drug Development Summit, Boston, Mass., November 12-14, 2024LSX Investival Showcase, London, UK, November 18, 2024 To schedule a meeting with Edesa during the conferences, please contact conference organizers or the company directly at [email protected]. About Edesa Biotech, Inc. Edesa Biote
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business. During the quarter, the company's anti-TLR4 drug candidate, EB05 (paridiprubart), was selected by the U.S. Department of Health and Human Services for use in a U.S. government-funded platform study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Edesa is providing drug product for the trial as
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes.This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS.Paridiprubart was selected following a competitive review process of multiple host-directed therapeutic candidates.TORONTO, ON / ACCESSWIRE / June 24, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, announced today that its first-in-class drug candidate has been selected by the Biomedical Advance
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business.During the quarter, the company expanded site selection activities for a Phase 3 study of its ARDS (Acute Respiratory Distress Syndrome) drug candidate, EB05 (paridiprubart). Edesa previously secured up to C$23 million from the Canadian government toward the development of EB05, a portion of which is conditionally repayable. The company also intends to evaluate EB05, an an
DEFA14A - Edesa Biotech, Inc. (0001540159) (Filer)
DEF 14A - Edesa Biotech, Inc. (0001540159) (Filer)
8-K - Edesa Biotech, Inc. (0001540159) (Filer)
EFFECT - Edesa Biotech, Inc. (0001540159) (Filer)
424B3 - Edesa Biotech, Inc. (0001540159) (Filer)
S-3 - Edesa Biotech, Inc. (0001540159) (Filer)
SCHEDULE 13G - Edesa Biotech, Inc. (0001540159) (Subject)
SCHEDULE 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)
SCHEDULE 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)
D - Edesa Biotech, Inc. (0001540159) (Filer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
3 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
3 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
4 - Edesa Biotech, Inc. (0001540159) (Issuer)
HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph
TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner
TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily
TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of a key member to its management team to support the company's expanding manufacturing activities.Rajan Puri has been appointed to the newly established position of Senior Vice President of Manufacturing. Mr. Puri is an expert in Chemistry, Manufacturing and Controls (CMC) in the biopharmaceutical field and will lead the company's strategic planning and operations related to scale-up, manufacturing and quality control."We are pleased to welcome Raj to our management team in anticipation o
TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020. Dear Fellow Shareholders, It would be difficult to begin any year-end review without acknowledging the impact that the global health crisis has had on our communities and families, our economy, and on our operations. 2020 has been anything but an ordinary year. While Edesa's first full year as a public company brought unexpected challenges, it also brought opportunities to demonstrate the flexibility and breadth of our clinical development strategy. During th
SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)
SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)